Coherus Biosciences | CHRS - Capitale Sociale E Riserve





Capitale Sociale E Riserve Cambiamento Data
AbbVie USD -6.66B 3.39B 2026-03
Acadia Pharmaceuticals USD 1.25B 20.68M 2026-03
Akebia Therapeutics USD 27.38M 5.24M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Alnylam Pharmaceuticals USD 1.08B 286.2M 2026-03
Amarin USD 449.41M 9.87M 2026-03
Amgen USD 9.19B 532M 2026-03
Baxter International USD 6.04B 86M 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Fujifilm JPY 3.84T 119.25B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
Ironwood Pharmaceuticals USD -217.14M 44.69M 2026-03
Merck USD 45.88B 6.73B 2026-03
Myriad Genetics USD 337.4M 30.6M 2026-03
Pacira USD 653.89M 39.22M 2026-03
Perrigo USD 2.5B 436.7M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
PTC Therapeutics USD -180.46M 24.85M 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Sarepta Therapeutics USD 1.51B 364.48M 2026-03
Teva Pharmaceutical Industries USD 8.23B 314M 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Xencor USD 515.63M 119.95M 2026-03
Zoetis USD 3.23B 98M 2026-03